Longitudinal Analyses of Antibody Responses to SARS-CoV-2

SARS-CoV-2 抗体反应的纵向分析

• 批准号: 10688391
• 负责人: JAMES E Robinson
• 金额: $ 51.01万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10688391
• 关键词: 2019-nCoV; Address; Antibodies; Antibody Response; Antibody-mediated protection; Area; Biological Assay; COVID-19; Clinical; Communities; Country; Data; Data Set; Development; Disease; Epidemic; Evolution; Exposure to; Follow-Up Studies; Future; Human; Humoral Immunities; Immune; Immune response; Immunity; Immunoassay; Immunocompetent; Immunologic Deficiency Syndromes; Immunologic Memory; Individual; Infection; Knowledge; Longitudinal Studies; Longterm Follow-up; Malignant Neoplasms; Measurement; Measures; Methodology; Patients; Persons; Population; SARS coronavirus; SARS-CoV-2 antibody; SARS-CoV-2 immunity; SARS-CoV-2 infection; Serology; Serology test; Seroprevalences; Shapes; Standardization; T-Lymphocyte; Testing; Time; Universities; Virus; antibody test; cohort; coronavirus disease; human subject; immune function; insight; longitudinal analysis; novel; pandemic disease; response; seasonal coronavirus; tool

Project 1 Summary We will conduct comprehensive studies of immune responses in human subjects who have current or past infections with SARS-CoV-2. An overarching aim is to understand whether immune responses to CoV-2 infections confer protection against future repeat episodes of COVID19 and whether CoV-2 immunity is long lasting. We propose the hypothesis that once immunocompetent human beings have had any form of COVID19, they will never get the full disease again. On the other hand, long term follow-up studies of CoV-2 immunity in patients with cancer or any cause of immunodeficiency will include plans to look for reinfection and repeat episodes of COVID19. There is a clear need for accurate serologic assays to determine who in a given community has had infection with SARS CoV-2. Many assays marketed early in the pandemic are prone to false positive and negative results. We plan to validate our efficient and sensitive immunoassays for routine serodiagnosis of SARS CoV-2 infections. It should be admitted that even the best assay is going miss unusual cases where a person tested positive by PCR but shows up negative in antibody tests. Although the antibody assay could be falsely negative, it is also possible that the person was truly infected by did not develop humoral immunity. In project 2, we will test the possibility that measuring T cell immunity may confirm that even some antibody negative patients have immunity to the virus after all.

项目1摘要 我们将对目前或过去患有癌症的人类受试者的免疫反应进行全面研究。 感染SARS-CoV-2。首要目标是了解对CoV-2的免疫反应是否 感染可防止未来COVID 19的重复发作，以及CoV-2免疫力是否持久 持久我们提出假设，一旦有免疫能力的人有任何形式的免疫缺陷， COVID 19，他们再也不会得到完整的疾病。另一方面，CoV-2的长期随访研究 癌症或任何免疫缺陷原因的患者的免疫将包括寻找再感染的计划， COVID 19的重复发作。显然需要准确的血清学检测来确定在给定的 社区感染了SARS CoV-2。在大流行早期上市的许多检测试剂盒易于 假阳性和阴性结果。我们计划验证我们的高效和灵敏的免疫测定法， SARS CoV-2感染的血清学诊断。应该承认，即使是最好的分析也会错过不寻常的 一个人通过PCR检测呈阳性，但在抗体检测中呈阴性的情况。虽然抗体 检测可能是假阴性，也有可能是人真的感染了没有发展 体液免疫在项目2中，我们将测试测量T细胞免疫力可能证实， 即使是一些抗体阴性的病人，毕竟对病毒也有免疫力。